A new world for unicorns: What the WeWork flop means for Seattle’s top startups and IPO prospects WeWork’s dramatic fall from grace, which saw its valuation fall from $47 billion to a reported $8 billion amid an… Read More
Adaptive Biotechnologies set to go public with valuation above $2B in biggest biotech IPO of 2019 Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash… Read More
Adaptive Biotechnologies files for $230M IPO, banking on big Microsoft and Genentech deals Adaptive Biotechnologies, a high-flying startup that makes technology to read the human immune system, has officially filed to go public… Read More
